Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Market: Pharmaceuticals and Healthcare

Global, 133 pages report, published by GBI Research

Report ThumbnailDecember-2016
Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons,

Read More
  • 1.2 List of Figures
  • Figure 1: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Alzheimer’s Disease (‘000), 2015-2022 24
  • Figure 2: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Parkinson’s Disease (‘000), 2015-2022 25
  • Figure 3: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Huntington’s Disease (‘000), 2015-2022 26
  • Figure 4: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Amyotrophic
Read More
  • 1.1 List of Tables
  • Table 1: Neurodegenerative Disorders Therapeutics Market, Symptoms of AD, PD, HD, ALS and MS, 2016 14
  • Table 2: Neurodegenerative Disorders Therapeutics Market, Etiology of AD, PD, HD, ALS and MS, 2016 16
  • Table 3: Neurodegenerative Disorders , Global, Epidemiology of Neurodegenerative Disorders, 2016 23
  • Table 4: Neurodegenerative Disorders Therapeutics Market, Comorbidities Associated with AD, PD, HD, ALS and MS, 2016 29
  • Table 5: Neurodegenerative Disorders Therapeutics Market,
Read More
  • 1 Table of Contents
  • 1 Table of Contents 5
  • 1.1 List of Tables 7
  • 1.2 List of Figures 7
  • 2 Introduction 10
  • 2.1 Therapy Area Introduction 10
  • 2.1.1 Alzheimer’s Disease 10
  • 2.1.2 Parkinson’s Disease 11
  • 2.1.3 Huntington’s Disease 11
  • 2.1.4 Amyotrophic Lateral Sclerosis 12
  • 2.1.5 Multiple Sclerosis 13
  • 2.2 Symptoms 14
  • 2.3 Etiology and Pathophysiology 15
  • 2.3.1 Pathophysiology 18
  • 2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 22
  • 2.4.1 Alzheimer’s Disease 2
Read More
  • Global neurodegenerative drugs market set to hit $45 billion by 2022, says GBI Research

    The neurodegenerative disorders market, which covers Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and multiple sclerosis (MS), is set to grow from $27.2 billion in 2015 to $45 billion by 2022, at a compound annual growth rate of 7.42%, according to business intelligence provider GBI Research.

    The company’s latest report states that much of this growth
Read More

Related Products

GBI ResearchGlobal Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory TreatmentsProduct ThumbnailGlobal Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments, Industry ReportProduct #: 631436
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved